On November 22, 2021 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, reported two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 (Press release, Adagene, NOV 22, 2021, View Source [SID1234595952]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The conference abstracts are expected to be published on the ESMO (Free ESMO Whitepaper)-IO website on Thursday, December 2, 2021 and posters available on Monday, December 6, 2021 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from December 8 to 11, 2021.
"These clinical data from two of our ongoing NEObody clinical programs showcase the importance of our pioneering approach to target a unique epitope and reflect the dynamic interactivity between an antibody and antigen," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. "The pharmacodynamic biomarker findings from our ongoing ADG106 trial with the anti-PD-1 toripalimab reinforce the potential synergistic combination for strong T-cell activation. For our novel anti-CTLA-4 program, data from the ongoing dose escalation of ADG116 monotherapy support the robust safety profile and dose dependent T-cell activation in both hot and cold tumors, suggesting potential clinical benefit following our translational studies. Each of these analyses highlights the promise of our tailor-made programs to achieve the fine balance between safety and efficacy – thereby unlocking the full value of some of the most promising yet challenging immuno-oncology targets today."
Details for the poster presentations during ESMO (Free ESMO Whitepaper)-IO 2021 include:
·Title: Assessment of Biomarker Kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab
Presentation Number: 43P
Date: Monday, December 6, 2021
Time: 12:00 Central European Time
·Title: Phase 1 dose-finding study of a novel anti–CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
Presentation Number: 137P
Date: Monday, December 6, 2021
Time: 12:00 Central European Time
Both the ADG106 and ADG116 programs use Adagene’s innovative NEObody technology, which enables targeting of unique and highly conserved epitopes against a broad range of antigens. These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies. The company is also developing an anti-CTLA-4 antibody, ADG126, using its SAFEbody precision masking technology.